MapLight Therapeutics, Inc. Common Stock (MPLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MapLight Therapeutics, Inc. Common Stock (MPLT) has a cash flow conversion efficiency ratio of -0.102x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.83 Million) by net assets ($458.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MapLight Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how MapLight Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MPLT liabilities breakdown for a breakdown of total debt and financial obligations.
MapLight Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MapLight Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Weibo Corporation
F:2WBA
|
0.063x |
|
Kuangda Technology Group Co Ltd
SHE:002516
|
0.026x |
|
S&S TECH Corporation
KQ:101490
|
0.045x |
|
Central Plaza Hotel Public Company Limited
BK:CENTEL
|
0.071x |
|
Gallant Micro Machining Co Ltd
TWO:6640
|
0.080x |
|
Westamerica Bancorporation
NASDAQ:WABC
|
0.032x |
|
LX International Corp
KO:001120
|
0.074x |
|
Laurentian Bank Of Canada
TO:LB
|
0.171x |
Annual Cash Flow Conversion Efficiency for MapLight Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see MapLight Therapeutics, Inc. Common Stock (MPLT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $458.37 Million | $-138.14 Million | -0.301x | +55.95% |
| 2024-12-31 | $115.19 Million | $-78.81 Million | -0.684x | +6.22% |
| 2023-12-31 | $71.28 Million | $-52.01 Million | -0.730x | +42.71% |
| 2022-12-31 | $20.87 Million | $-26.58 Million | -1.273x | -- |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more